Placebo News and Research

RSS

Powerful psychedelic compound can model near-death experiences in the brain

A powerful psychedelic compound found in ayahuasca can model near-death experiences in the brain, a study has found.

15 Aug 2018

Researchers discover new approach to alleviate chronic itch

Two receptors in the spinal cord and the right experimental drug: Researchers at the University of Zurich have discovered a new approach that suppresses itch.

14 Aug 2018

NIH grant for Mount Sinai to study use of inhaled corticosteroids for treatment of sickle cell disease

The Departments of Emergency Medicine and Hematology at the Icahn School of Medicine at Mount Sinai have been awarded a $4 million grant from the National Institutes of Health toward further study of inhaled corticosteroids to treat sickle cell disease in individuals who do not have asthma.

14 Aug 2018

FDA approves first oral medication for treatment of adults with Fabry disease

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

10 Aug 2018

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

New study investigates whether nicotine could slow memory loss

Can nicotine slow or stop memory loss in people experiencing mild memory problems, or mild cognitive impairment? A new study being conducted at Georgetown University Medical Center aims to find out.

9 Aug 2018

Extended-release naltrexone appears to help HIV-positive patients reduce heavy drinking

Extended-release naltrexone -- an injection that decreases heavy drinking in the general population when taken in conjunction with counseling -- appears to help HIV-positive individuals reduce their number of heavy drinking days too, say Yale researchers.

7 Aug 2018

Otsuka’s JINARC approved for treatment of patients with CKD stage 4 ADPKD

Otsuka Pharmaceutical Europe Ltd. today announced that the European Commission has approved an extension of indication for JINARC to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease

2 Aug 2018

Peer comparison letters lead to persistent decrease in antipsychotic prescribing

A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel, an antipsychotic with potentially harmful side effects in the elderly, significantly reduced the number of prescriptions for patients in Medicare.

2 Aug 2018

Exenatide treatment improves depression symptoms in PD patients

Non-motor symptoms of Parkinson's disease, such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits.

1 Aug 2018

New method to evaluate drug benefits may reduce health care costs

With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.

31 Jul 2018

New study provides insight into how stimulant treatments for ADHD work

Stimulant medications are an effective treatment for Attention-Deficit/Hyperactivity Disorder. In the classroom, parents and teachers say that medications like methylphenidate can reduce symptoms and improve behavior.

28 Jul 2018

Cannabis appears to have no effect on breathlessness during exercise in advanced COPD patients

Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease, according to a randomized controlled trial published online in the Annals of the American Thoracic Society.

27 Jul 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

27 Jul 2018

Therapy with L-Glutamine reduces pain in patients with sickle cell disease

UCSF Benioff Children's Hospital Oakland clinical researchers, in conjunction with other sickle cell centers and scientists at Emmaus Life Sciences, Inc., have demonstrated that therapy with L-Glutamine reduced the frequency of pain episodes in both pediatric and adult patients with sickle cell disease.

27 Jul 2018

New drug discovery system allows scientists to target ‘undruggable’ enzymes

A new drug discovery system allows scientists to specifically target members of an important family of enzymes, called phosphatases, which were previously considered mostly "undruggable".

27 Jul 2018

New drug offers hope to prevent attacks of hereditary angioedema

Hereditary angioedema is a chronic disorder that can sometimes be life-threatening. Now, a new drug therapy has been successfully tested in an international study headed by the University Hospital Frankfurt.

26 Jul 2018

Ciprofloxacin may disrupt normal functions of connective tissue

The use of ciprofloxacin and other antibiotics of the class of fluoroquinolones may be associated with disruption of the normal functions of connective tissue, including tendon rupture, tendonitis and retinal detachment

26 Jul 2018

Pivotal study of dasotraline in adults with binge eating disorder meets primary endpoint

Sunovion Pharmaceuticals Inc. today announced that a study evaluating the efficacy and safety of dasotraline in adults with moderate to severe binge eating disorder met its primary endpoint, demonstrating a statistically significant decrease in number of binge days per week from baseline to Week 12 in the group treated with dasotraline 6 mg/day versus the placebo-treated group.

25 Jul 2018